Global Alliance for TB Drug Development
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Global Alliance for TB Drug Development
The healthcare giant is investing heavily into partnerships designed to beat the two infectious diseases.
Long-time deputy John Farley becomes acting director of the Office of Antimicrobial Products. Cox, who served as the director of the office for more than a decade, joins Regeneron to serve as vice president of regulatory affairs.
The latest drug development news and highlights from our US FDA Performance Tracker.
Pink Sheet Podcast: Zolgensma Saga Continues, ICER Reviews DMD Drugs, FDA Issues Another LPAD Approval
Pink Sheet reporters review Novartis' latest response to Zolgensma data manipulation, discuss ICER reviews of Sarepta's Duchenne muscular dystrophy treatments, and recap the FDA's latest antibiotic approval.
- Academic and Research Institutions
- Other Names / Subsidiaries
- TB Alliance
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.